Shares of Nuvalent NUVL have soared nearly 20% in the past week owing to encouraging updates on its two investigational ...

Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best ...

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...

Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing ...

Scattered investor qualms about Nuvalent Inc.’s largely upbeat data during the European Society for Medical Oncology (ESMO) ...

Nuvalent, Inc. (NUVL), a company focused on cancer treatment, announced on Monday that it has commenced an underwritten public ...

Nuvalent Inc. (NUVL) announced the pricing of an upsized underwritten public offering of 5 million shares of Class A common stock at ...

We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to ...

Shares of Nuvalent rose after the company offered promising updates about the progress of its parallel lead cancer drug programs through clinical trials. The stock was up 20% at $105 in premarket ...

Analyst Rating Boosts Investor Confidence. Today, Stifel released a pivotal update on Nuvalent’s stock. The analyst firm maintained its “Buy” rating but raised the price tar ...

In terms of valuation, Nuvalent Inc’s market capitalization stands at $7.27 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.